Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs. Reumatismo [Internet]. 2021 Apr. 19 [cited 2025 Jun. 7];73(1):5-14. Available from: https://www.reumatismo.org/reuma/article/view/1329